172 results
8-K
HBIO
Harvard Bioscience Inc.
3 Jan 01
Current report
12:00am
could involve significant litigation-related expenses,
but that it will not have a material adverse effect on its financial condition
or results … of operations.
Pursuant to the safe harbor provisions of the Private Securities
Litigation Act of 1995, the Company notes that statements contained
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
7 Mar 24
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
7:00am
of intangibles related to acquisitions, litigation settlement, restructuring and other costs, unrealized gain/loss on equity securities, income taxes … forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
8 Nov 22
Harvard Bioscience Announces Third Quarter 2022 Financial Results
4:02pm
, and stock-based compensation expense, and litigation settlement expenses. They also exclude the tax impact of the reconciling items. Management believes … release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act
S-1/A
EX-10
HBIO
Harvard Bioscience Inc.
25 Oct 00
IPO registration (amended)
12:00am
capable persons available;
WHEREAS, increased corporate litigation has subjected directors to
litigation risks and expenses …
litigation risks and expenses (regardless, among other things, of any amendment
to or revocation of any such Certificate of Incorporation or By-laws or any
8-K
EX-99.1
g46e ixjrr
4 Aug 22
Harvard Bioscience Announces Second Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
ehm2ntkmwk sv491m
4 May 22
Harvard Bioscience Announces First Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
225us6564gvi762h ouh
25 Apr 23
Harvard Bioscience Announces First Quarter 2023 Financial Results
8:00am
8-K
EX-10.1
i5bkbzk
28 Apr 22
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
yj8zr8g0 1x9
8 Aug 23
Harvard Bioscience Announces Second Quarter 2023 Financial Results
9:05am
8-K
EX-2.1
b33e512xd49sjncl
18 Mar 04
Acquisition or disposition of assets
12:00am
8-K
4u3z032d
28 Apr 22
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99
cw1suqy5
19 Jul 02
Other events
12:00am
8-K
EX-10.2
92d6omt
8 Jul 19
Departure of Directors or Certain Officers
8:05am